Homoeopathic drug dilutions of Thuja occidentalis attenuate complete Freund's adjuvant-induced arthritis in Wistar rats

Context: Thuja occidentalis is prescribed in Homoeopathy in treating rheumatoid arthritis. We speculated the anti-arthritic mechanism of Homoeopathic dilutions of Thuja occidentalis against the complete Freund's adjuvant (CFA)-induced arthritis in rats. Materials and Methods: Arthritis was induced (n = 28) by subplantar injection of 0.1 ml CFA in the right hind paw of rats. The oral dose of crude Thuja occidentalis was 30 mg/kg/b. i. d and that of Homoeopathic dilutions was 0.1 ml/b. i. d. Orally administered diclofenac at 5 mg/kg/day served as a standard. The treatments continued for 24 days. The severity of arthritis was determined weekly as rise in paw volume, mechanical allodynia and changes in body weight. On the 25th day, X-ray imaging of the arthritic paws was recorded, and the biopsy samples extracted from the paws were subjected to the estimation of pro-inflammatory cytokines and histological evaluations. Results: Thuja occidentalis Homoeopathic dilutions and its crude form protected rats against the CFA-induced arthritic lesions. The mother tincture, 6cH, 30cH and 200cH dilutions of Thuja occidentalis significantly reduced the CFA-induced rise in paw volume, reduced the mechanical allodynia and also reduced the levels of interleukin (IL) IL-1, IL-6 and tumour necrosis factor alpha in paw tissue. CFA-induced articular changes, oedema, cellular infiltrations and cartilage damage were reduced by Thuja occidentalis dilutions. The radiological images indicated that Thuja occidentalis treatment reduced the CFA-induced joint swelling, bone erosion and joint space narrowing. Conclusion: Our findings substantiate the anti-arthritic effects of Thuja occidentalis Homoeopathic dilutions against CFA-induced arthritis and indicate that Homoeopathic dilutions of Thuja occidentalis, particularly 6cH dilution, exert more potent anti-arthritic effects than its crude form

In-Vitro Antioxidant Activity, Acute Oral Toxicity Studies and Preliminary Phytochemical Characterization of the Bark Extract of Terminalia arjuna (L.)

The free radicals and the reactive oxygen species (ROS) are known to induce oxidative stress and it has been implicated in the pathology of cardiovascular diseases, inflammatory conditions, cancer and ageing. The activities associated with ROS can bedelayed, prevented or removedby antioxidant compounds (natural or synthetic). The use of synthetic antioxidants restricted because of their known side effects such as liver damage and carcinogenesis. The aim of this study to evaluate in vitro antioxidant and acute oral toxicity of Terminalia arjuna extracts. The present finding reveals that the purified fraction at100 µg/ml, showed maximum (91.32 ± 0.10 %,) DPPH radical scavenging effect in comparison with standard ascorbic acid (79.46 ± 0.10%) at the 10 µg/ml concentration. The reducing power of the purified extract was found to be dose dependent. Food and water intake of the animals in test and control groups was found normal during the 14 day acute oral toxicity studies and no apparent changes were observed in the internal organs of both, the test and control groups, after gross necropsy. The preliminary phytochemical screening of the crude acetone extract revealed dominant presence steroids, terpenoids, polyphenols, alkaloids and tannins. TLC profile of the purified fraction revealed a single band of Rf 0.38, a characteristic feature of triterpenoids. The UV absorption maximum of the purified fraction was recorded at 194nm. The FT-IR spectrum indicated presence of aromatic rings 3421 (COOH), 2957 (alkanes, CH2 and CH3), 1726 (carbonyl), 1599 (carboxylic acid), and region between 1000-1300 stretching of C-O, ester and ether carboxylic group. Thus, the isolated bioactive phytoconstituents form the bark extract of Terminalia arjuna could be used as natural anti-oxidants.

Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals

Inflammation is one of the common events in the majority of acute as well as chronic debilitating diseases and represent a chief cause of morbidity in today’s era of modern lifestyle. If unchecked, inflammation leads to development of rheumatoid arthritis, diabetes, cancer, Alzheimer’s disease, and atherosclerosis along with pulmonary, autoimmune and cardiovascular diseases. Inflammation involves a complex network of many mediators, a variety of cells, and execution of multiple pathways. Current therapy for inflammatory diseases is limited to the steroidal and non-steroidal anti-inflammatory agents. The chronic use of these drugs is reported to cause severe adverse effects like gastrointestinal, cardiovascular, and renal abnormalities. There is a massive need to explore new anti-inflammatory agents with selective action and lesser toxicity. Plants and isolated phytoconstituents are promising and interesting sources of new anti-inflammatories. However, drug development from natural sources has been linked with hurdles like the complex nature of extracts, difficulties in isolation of pure phytoconstituents, and the yield of isolated compounds in minute quantities that is insufficient for subsequent lead development. Although various in-vivo and in-vitro models for anti-inflammatory drug development are available, judicious selection of appropriate animal models is a vital step in the early phase of drug development. Systematic evaluation of phytoconstituents can facilitate the identification and development of potential anti-inflammatory leads from natural sources. The present review describes various techniques of anti-inflammatory drug screening with its advantages and limitations, elaboration on biological targets of phytoconstituents in inflammation and biomarkers for the prediction of adverse effects of anti-inflammatory drugs. The systematic approach proposed through present article for anti-inflammatory drug screening can rationalize the identification of novel phytoconstituents at the initial stage of drug screening programs